Your session is about to expire
← Back to Search
BETA-Text text messaging intervention for Breast Cancer
N/A
Waitlist Available
Led By Sarah Mougalian, MD
Research Sponsored by Yale University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights
Study Summary
This trial is comparing rates of continuation of any endocrine therapy between patients who only have standard of care follow-up and those who also have a bi-directional text messaging intervention. The secondary objectives are to assess time to permanent discontinuation of endocrine therapy, quality of life, adherence self-efficacy, financial burden, beliefs about medications, and perceived ability to communicate with one's physician.
Eligible Conditions
- Breast Cancer
- Medication Adherence
- Side Effects
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 1 year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Persistence to endocrine therapy at one year
Secondary outcome measures
Adherence self-efficacy
Beliefs about medication
Communication with one's physician
+8 moreTrial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: BETA-Text InterventionExperimental Treatment1 Intervention
Patients in the text messaging arm will receive daily, weekly, and monthly text messages.
Group II: Usual CareActive Control1 Intervention
Patients in the usual care arm will not receive any text messages.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
BETA-Text text messaging intervention
2019
N/A
~400
Find a Location
Who is running the clinical trial?
Yale UniversityLead Sponsor
1,865 Previous Clinical Trials
2,742,345 Total Patients Enrolled
26 Trials studying Breast Cancer
2,835 Patients Enrolled for Breast Cancer
Sarah Mougalian, MDPrincipal InvestigatorYale University
1 Previous Clinical Trials
100 Total Patients Enrolled
1 Trials studying Breast Cancer
100 Patients Enrolled for Breast Cancer
Share this study with friends
Copy Link
Messenger